Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: teriparatide
INDICATION: Osteoporosis
DATE: 12/01/2023
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
